Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | CHRNG | P07510 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523840 | 0.94 | KCNN4 (0.51) | KCNN4CYP2C9CYP2D6HIF1AAKR1C3 | |
| SCHEMBL29798913 | 0.94 | KCNN4 (0.51) | KCNN4CYP2C9CYP2D6HIF1AAKR1C3 | |
| Bromoethane SCHEMBL3169309 | 0.91 | KCNN4 (0.44) | KCNN4CYP2C9CYP2D6HIF1AAKR1C3 | |
| Bromomethane SCHEMBL3178733 | 0.84 | CYP2C9 (0.46) | KCNN4CYP2C9CYP2D6HIF1AAKR1C3 | |
| Bromomethane SCHEMBL3169191 | 0.84 | CYP2C9 (0.46) | CYP2C9CYP2D6HIF1AAKR1C3AKR1C2 | |
| Bromomethane SCHEMBL4021492 | 0.81 | KCNN4 (0.47) | KCNN4CYP2C9AKR1C3AKR1C2APP | |
| Pseudotropine SCHEMBL3168855 | 0.80 | CYP2C9 (0.41) | KCNN4CYP2C9CYP2D6HIF1ACHRM3 | |
| Bromomethane SCHEMBL208552 | 0.79 | CYP2C9 (0.55) | KCNN4CYP2C9CYP2D6HIF1ACES2 | |
| SCHEMBL3179071 | 0.78 | CYP2C9 (0.46) | KCNN4CYP2C9CYP2D6HIF1AAKR1C3 | |
| SCHEMBL3173667 | 0.78 | CYP2C9 (0.46) | CYP2C9CYP2D6HIF1AAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652138-B2 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-26 | — | — | US | claimed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| EP-2326374-B1 | INHALER | BOEHRINGER INGELHEIM INT (DE) | 2020-03-04 | — | — | EP | disclosed |
| US-20200048278-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | BOEHRINGER INGELHEIM INT (DE) | 2020-02-13 | — | — | US | disclosed |
| US-10556069-B2 | Inhaler | LUPIN LIMITED (IN) | 2020-02-11 | — | — | US | disclosed |
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-10-03 | — | — | US | disclosed |
| US-20060002863-A1 | Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | US | disclosed |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050234134-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-20 | — | — | US | disclosed |
| US-6951888-B2 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-04 | — | — | US | disclosed |
| US-20050154555-A1 | Measuring device for rapid non-destructive measurement of the contents of capsules | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6852728-B2 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-02-08 | — | — | US | disclosed |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048278-A1 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA | CBS, CYSLTR1, DHPS | KCNN4 3218/4885CYP2C9 250/4885CYP2D6 73/4885 |
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | KCNN4 4745/4885CYP2C9 1982/4885CYP2D6 1790/4885 |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | KCNN4 4745/4885CYP2C9 1982/4885CYP2D6 1790/4885 |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | CBS, DHPS, TPMT | KCNN4 3351/4885CYP2C9 198/4885CYP2D6 57/4885 |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | ADRB1, ADRB2, ADRA1D | KCNN4 741/4885CYP2C9 715/4885CYP2D6 722/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | KCNN4 4745/4885CYP2C9 1982/4885CYP2D6 1790/4885 |
| US-20020119991-A1 | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them | CHRM1, CHRM3, CHRM2 | KCNN4 280/4885CYP2C9 368/4885CYP2D6 162/4885 |
| US-20050234134-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | CHRM1, CHRM2, ADRB1 | KCNN4 133/4885CYP2C9 297/4885CYP2D6 157/4885 |
| US-20040122108-A1 | Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions | ADRA2C, ADRA1D, ADRB1 | KCNN4 130/4885CYP2C9 453/4885CYP2D6 252/4885 |
| US-20050054664-A1 | Anticholinergics, processes for preparing them and pharmaceutical composition containing them | CHRM1, CHRM3, CHRM2 | KCNN4 248/4885CYP2C9 162/4885CYP2D6 147/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | KCNN4 3581/4885CYP2C9 3425/4885CYP2D6 1222/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | KCNN4 4745/4885CYP2C9 1982/4885CYP2D6 1790/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | KCNN4 4745/4885CYP2C9 1982/4885CYP2D6 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.